검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | MDX-1106 |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Carcinoma, Non-Small-Cell Lung |
Overview Indication | Carcinoma, Non-Small-Cell Lung; Colorectal Cancer |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | target FGF-2 and its receptors, inactivating the FGF-2/FGFR1/2 pathway |
MoA Biomarker | PD-1 molecules on circulating T cells ≥ 2 months follow |
PK/PD Half-life | 20 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates.. Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-re… |
Clinical Primary efficacy | ORR 20.1% |
Clinical ORR | 20.1% |
Clinical PFS | 4.04 |
Clinical OS | 13.70 |
Clinical Result source | ClinicalTrials.gov NCT03143153 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | MDX-1106 |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Carcinoma, Non-Small-Cell Lung |
Overview Indication | Carcinoma, Non-Small-Cell Lung; Colorectal Cancer |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | target FGF-2 and its receptors, inactivating the FGF-2/FGFR1/2 pathway |
MoA Biomarker | PD-1 molecules on circulating T cells ≥ 2 months follow |
PK/PD Half-life | 20 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates.. Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-re… |
Clinical Primary efficacy | ORR 20.1% |
Clinical ORR | 20.1% |
Clinical PFS | 4.04 |
Clinical OS | 13.70 |
Clinical Result source | ClinicalTrials.gov NCT03143153 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교